Publications by authors named "Eric Leip"

Claim this Profile
E
Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.
Carlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, Kevin R Kelly, Vivian G Oehler, Eric Leip

Leukemia· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study.
Michael H Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J Bahlis, Eric Leip

Hemasphere· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
B Douglas Smith, Tim H Brümmendorf, Gail J Roboz, Carlo Gambacorti-Passerini, Aude Charbonnier, Eric Leip

Leuk Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study.
Jorge E Cortes, Jeff H Lipton, Vamsi Kota, Fausto Castagnetti, Sarit Assouline, Eric Leip

Haematologica· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Alexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, Nizar J Bahlis, H Miles Prince, Eric Leip

Nat Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
Tim H Brümmendorf, Jorge E Cortes, Dragana Milojkovic, Carlo Gambacorti-Passerini, Richard E Clark, Eric Leip

Leukemia· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.
Vamsi Kota, Tim H Brümmendorf, Carlo Gambacorti-Passerini, Jeff H Lipton, Dong-Wook Kim, Eric Leip

Leuk Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy.
Jorge E Cortes, Hagop M Kantarjian, Michael J Mauro, Fiona An, Sonja Nick, Eric Leip

Eur J Haematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
Bogdan Muresan, Carla Mamolo, Joseph C Cappelleri, Eric Leip, Andrea Viqueira

Curr Med Res Opin· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
Andreas Hochhaus, Carlo Gambacorti-Passerini, Camille Abboud, Bjørn Tore Gjertsen, Tim H Brümmendorf, Eric Leip

Leukemia· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.
Jorge E Cortes, Hervé Dombret, Akil Merchant, Tetsuzo Tauchi, Christine G DiRienzo, Eric P Leip

Future Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Carlo Gambacorti-Passerini, Jorge E Cortes, Jeff H Lipton, Hagop M Kantarjian, Dong-Wook Kim, Eric Leip

Haematologica· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Jorge E Cortes, Carlo Gambacorti-Passerini, Michael W Deininger, Michael J Mauro, Charles Chuah, Eric Leip

J Clin Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.
Jorge E Cortes, Carlo Gambacorti-Passerini, Dong-Wook Kim, Hagop M Kantarjian, Jeff H Lipton, Eric Leip

Clin Lymphoma Myeloma Leuk· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
Jorge E Cortes, Hanna J Khoury, Hagop M Kantarjian, Jeff H Lipton, Dong-Wook Kim, Eric Leip

Am J Hematol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
Jorge E Cortes, H Jean Khoury, Hagop Kantarjian, Tim H Brümmendorf, Michael J Mauro, Eric Leip

Am J Hematol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Tim H Brümmendorf, Jorge E Cortes, Hanna J Khoury, Hagop M Kantarjian, Dong-Wook Kim, Eric Leip

Br J Haematol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
Carlo Gambacorti-Passerini, Hagop M Kantarjian, Dong-Wook Kim, Hanna J Khoury, Anna G Turkina, Eric Leip

Am J Hematol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
Carlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, Anna G Turkina, Tamas Masszi, Eric Leip

Am J Hematol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Beverly Moy, Patrick Neven, Fabienne Lebrun, Meritxell Bellet, Binghe Xu, Eric Leip

Oncologist· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Beverly Moy, Patrick Neven, Fabienne Lebrun, Meritxell Bellet, Binghe Xu, Eric Leip

Oncologist· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Hagop M Kantarjian, Jorge E Cortes, Dong-Wook Kim, H Jean Khoury, Tim H Brümmendorf, Eric Leip

Blood· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
H Jean Khoury, Jorge E Cortes, Hagop M Kantarjian, Carlo Gambacorti-Passerini, Michele Baccarani, Eric Leip

Blood· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
Adil I Daud, Smitha S Krishnamurthi, Mansoor N Saleh, Barbara J Gitlitz, Mitesh J Borad, Eric Leip

Clin Cancer Res· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Jorge E Cortes, Hagop M Kantarjian, Tim H Brümmendorf, Dong-Wook Kim, Anna G Turkina, Eric Leip

Blood· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis